the relatively rapid advances in molecular pharmacology of one of our most important receptor classes, clinical development, as described by Power, 2 has been slow. However, the advent of significant new molecules such as tapentadol and the reuse of old drugs in combination (e.g. morphine/ oxycodone and oxycodone/naloxone) are already in the clinic. The effective use of new (and old) drugs clearly relies on accurate diagnosis and Niraj and Rowbotham 3 provide
an overview of where we are currently and reinforce the advice that (i) severe postoperative pain is associated with persistent pain, and (ii) early management of persistent postoperative pain may reduce its longevity and severity. Drug-related adverse events are covered in some detail by Mahajan, 4 Hudson and Hemmings, 5 and Hopkins, 6 who deal with drug errors, central nervous system (CNS) toxicity, and malignant hyperthermia (MH) triggering, respectively. Mahajan 4 highlights the slow uptake of mechanisms to prevent human error in the high-risk and high-pressure environment of anaesthesia and ends his review with the clear warning 'Society will be justified in making harsh judgements if we allow continuing inertia to delay the implementation of measures to prevent drug errors and improve patient safety'. Hudson and Hemmings, in their review of CNS toxicity, 5 emphasize the potential for adverse effects, especially at extremes of age, despite the apparently neuroprotective abilities of xenon; 7 however, they caution that the much-needed prospective clinical trials will be a challenge to design, especially in standardizing exposure and measuring outcome. In his review of the triggering of MH, 6 Hopkins debunks the commonly held view that modern volatile agents may be safe to use in patients susceptible to MH and argues that suxamethonium may not be the potent triggering agent previously assumed. Gray, a true pioneer in anaesthesia. In a tale of daring, dogged persistence, inspiration, remarkable graft, and some practices that we might consider ethically 'interesting' in the modern day, Shafer provides an intriguing and inspiring biography of this giant in the field of anaesthesia.
In the research strategy report 14 The end of the 20th century has been considered by some to have encompassed difficult times with anaesthesia-related research a little gloomy, but what has emerged in the first decade of this new century is a strong, vibrant speciality better equipped for the significant research challenges of the next decade and beyond. Novel directions such as less invasive monitoring, 16 in silico investigation, 17 genomics, 18 human factors, 19 and novel drugs 20 offer exciting possibilities for improving the care we offer our patients. The future is bright.
